^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FOXO3 rs4946935

    i
    Other names: FOXO3, AF6q21, FKHRL1, FOXO2, FOXO3A, Forkhead box O3
    Entrez ID:
    2309
    Related biomarkers:
    Expression
    Mutation
    Associations

    News

    Trials
    2years
    FOXO3 mutation predicting gefitinib-induced hepatotoxicity in NSCLC patients through regulation of autophagy. (PubMed, Acta Pharm Sin B)
    This study reveals that FOXO3 mutation, leading to autophagic imbalance, plays important role in gefitinib-induced hepatotoxicity, especially for patients with high concentration of gefitinib. In conclusion, FOXO3 mutation is an effective predictor and erlotinib might be an appropriately and well-tolerated treatment option for patients carrying rs4946935 AA.
    Journal
    |
    FOXO3 (Forkhead box O3)
    |
    FOXO3 rs4946935
    |
    erlotinib • gefitinib
    over4years
    [VIRTUAL] FOXO3 polymorphisms were correlated with gefitinib-induced hepatotoxicity in patients with non-small cell lung cancer. (ASCO 2020)
    FOXO3 rs4946935 and FOXO3 rs75544369 are predictive biomarkers for gefitinib-induced hepatotoxicity in NSCLC patients. The mechanism underlying the association between FOXO3 polymorphisms and gefitinib-induced hepatotoxicity are worth investigating in further studies. Research Funding: National Natural Science Foundation of China
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • FOXO3 (Forkhead box O3)
    |
    EGFR mutation • FOXO3 rs4946935 • FOXO3 rs75544369
    |
    gefitinib